An Overview of New Biologics for Migraine Prophylaxis

Philip Harvey, PharmD/MBA Candidate 2020; Pooja Shah, PharmD/MBA Candidate 2020; Scott Shipley, PharmD, BCPS


US Pharmacist. 2020;45(1):21-24. 

In This Article

Cost Comparison

The estimated cost of erenumab, fremanezumab, and galcanezumab is approximately $575 per month, or approximately $5,000 annually. The Institute for Clinical and Economic Review determined that prices for CGRP antagonist treatments align with the value to patients who failed other preventive therapies. Assistance programs for these medications are available through the manufacturer, providing up to a no-cost 1-year supply or out-of-pocket expense assistance for certain patients with commercial insurance. These agents are shown to be cost-effective for the patient in the long term.[17] The AHS pointed out that in order to achieve cost-effective care while ensuring access for those patients most appropriate for these treatments, it is important that the indications for initiating treatment with CGRP antagonists are well understood.[18]